<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04022291</url>
  </required_header>
  <id_info>
    <org_study_id>EQ7030</org_study_id>
    <nct_id>NCT04022291</nct_id>
  </id_info>
  <brief_title>Comparison of Pharmacokinetic (PK) and Pharmacodynamic(PD) of Biocon Insulin 70/30 and Humulin® 70/30</brief_title>
  <official_title>A Randomised, Double-blind, Two-period Crossover, Euglycaemic Glucose Clamp Study in Healthy Volunteers to Demonstrate Pharmacokinetic and Pharmacodynamic Similarity of Biocon Insulin 70/30 and Humulin® 70/30</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biocon Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Profil Institut für Stoffwechselforschung GmbH</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Biocon Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Two-centre, randomised, double-blind, single dose, two-treatment, two-period, two sequence,
      crossover, 24-hour euglycaemic glucose clamp trial in healthy subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The present study is designed to demonstrate pharmacokinetic and pharmacodynamic equivalence
      of Biocon Insulin 70/30 with Humulin® 70/30 in healthy subjects The treatment consists of one
      single dose of the test or reference product, administered during each of the two study
      periods, separated by 5-7 days between dosing. The planned trial duration for each subject is
      about 12 to 36 days.

      Eligible subjects will undergo two 24-hour euglycaemic clamp examinations, one after
      administration of the test product and one after administration of the reference product in
      random order.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 15, 2019</start_date>
  <completion_date type="Actual">January 27, 2020</completion_date>
  <primary_completion_date type="Actual">January 20, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Double-blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic endpoints: area under the insulin concentration curve (AUCins) 0-24h</measure>
    <time_frame>0-24hour</time_frame>
    <description>area under the insulin concentration curve</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic endpoints: insulin concentration (Cins).max</measure>
    <time_frame>0-24hour</time_frame>
    <description>maximum observed insulin concentration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacodynamic Endpoint: Area under curve (AUC)Glucose infusion rate (GIR).0-24h</measure>
    <time_frame>0-24hour</time_frame>
    <description>area under the glucose infusion rate curve</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacodynamic Endpoint: maximum glucose infusion rate (GIRmax)</measure>
    <time_frame>0-24hour</time_frame>
    <description>maximum glucose infusion rate</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic endpoint: area under the insulin concentration curve(AUCins) 0-2h</measure>
    <time_frame>0-2hour</time_frame>
    <description>area under the insulin concentration curve</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic endpoint: area under the insulin concentration curve(AUCins) 0-6h</measure>
    <time_frame>0-6hour</time_frame>
    <description>area under the insulin concentration curve</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic endpoint: area under the insulin concentration curve(AUCins) 0-12h</measure>
    <time_frame>0-12hour</time_frame>
    <description>area under the insulin concentration curve</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic endpoint: area under the insulin concentration curve(AUCins)12-24h</measure>
    <time_frame>12-24hour</time_frame>
    <description>area under the insulin concentration curve</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic endpoint: area under the insulin concentration curve(AUCins).0-infinity</measure>
    <time_frame>0 to 24 hours</time_frame>
    <description>area under the insulin concentration curve</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic endpoint: time to maximum observed insulin concentration (tmax)</measure>
    <time_frame>0-24hour</time_frame>
    <description>time to maximum observed insulin concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic endpoint: time(t)50%-ins(early)</measure>
    <time_frame>0-24hour</time_frame>
    <description>time to half-maximum before Cins.max</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic endpoint: time(t)50%-ins(late)</measure>
    <time_frame>0-24hour</time_frame>
    <description>time to half-maximum after Cins.max</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic endpoint: terminal elimination half-life (t½)</measure>
    <time_frame>0-24hour</time_frame>
    <description>terminal elimination half-life calculated as t½=ln2/λz</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic endpoint:terminal elimination rate constant(λz)</measure>
    <time_frame>0-24hour</time_frame>
    <description>terminal elimination rate constant of insulin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic endpoints: area under the glucose infusion rate curve (AUCGIR) 0-2h</measure>
    <time_frame>0-2hour</time_frame>
    <description>area under the glucose infusion rate curve</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic endpoints: area under the glucose infusion rate curve (AUCGIR)0-6h</measure>
    <time_frame>0-6hour</time_frame>
    <description>area under the glucose infusion rate curve</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic endpoints: area under the glucose infusion rate curve(AUCGIR)0-12h</measure>
    <time_frame>0-12hour</time_frame>
    <description>area under the glucose infusion rate curve</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic endpoints: area under the glucose infusion rate curve (AUCGIR)12-24h</measure>
    <time_frame>12-24hour</time_frame>
    <description>area under the glucose infusion rate curve</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic endpoints: time to maximum glucose infusion rate (tGIR.max)</measure>
    <time_frame>0-24hour</time_frame>
    <description>time to maximum glucose infusion rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic endpoints: time to half-maximum glucose infusion rate before GIRmax(tGIR.50%-early)</measure>
    <time_frame>0-24hour</time_frame>
    <description>time to half-maximum glucose infusion rate before Maximum glucose infusion rate(GIRmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic endpoints: time to half-maximum glucose infusion rate after GIRmax (tGIR.50%-late)</measure>
    <time_frame>0-24hour</time_frame>
    <description>time to half-maximum glucose infusion rate after Maximum glucose infusion rate(GIRmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic endpoints: Onset of action</measure>
    <time_frame>0-24hour</time_frame>
    <description>time from trial product administration until blood glucose concentration has decreased at least 5 mg/dL from baseline, where baseline is defined as the mean of blood glucose levels from -6, -4, and -2 minutes before trial product administration as measured by ClampArt(name of Clamp Devise).</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Safety endpoints: Number of subjects with Adverse Events, clinically significant changes in Physical examination, Vital signs. Local tolerability/ Injection site reactions</measure>
    <time_frame>First dose to followup period (Total duration: 14 days approximate)</time_frame>
    <description>Number of subjects with Adverse Events, clinically significant changes in Physical examination, Vital signs
Local tolerability/ Injection site reactions</description>
  </other_outcome>
  <other_outcome>
    <measure>Safety endpoint: Number of subjects with clinically significant changes in Laboratory safety parameters, Electrocardiogram (ECG)</measure>
    <time_frame>Screening and Follow-up period (Total duration: 35 days approximate)</time_frame>
    <description>Number of subjects with clinically significant changes in Laboratory safety parameters.
Number of subjects with clinically significant changes in Electrocardiogram (ECG)</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">78</enrollment>
  <condition>Healthy Volunteer</condition>
  <arm_group>
    <arm_group_label>Biocon Insulin 70/30</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.4 IU/kg Dose per administration, Subcutaneous Route of administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Humulin® 70/30</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>0.4 IU/kg Dose per administration, Subcutaneous Route of administration</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Humulin ®70/30</intervention_name>
    <description>Humulin® 70/30 is a premixed suspension of human insulin of recombinant deoxyribonucleic acid (rDNA)origin, which contains 30% short-acting human soluble insulin and 70% intermediate-acting isophane insulin.
Human insulin is produced by recombinant deoxyribonucleic acid (rDNA), technology utilizing a non-pathogenic laboratory strain of Escherichia coli.</description>
    <arm_group_label>Humulin® 70/30</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Biocon Insulin 70/30</intervention_name>
    <description>Biocon Insulin 70/30 is a premixed suspension of human insulin of recombinant deoxyribonucleic acid (rDNA)origin, which contains 30% short-acting human soluble insulin and 70% intermediate-acting isophane insulin.
Biocon insulin is produced by recombinant deoxyribonucleic acid (rDNA) technology utilizing a non-pathogenic laboratory strain of Escherichia coli.</description>
    <arm_group_label>Biocon Insulin 70/30</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male or post-menopausal female subjects. Post-menopausal state is defined as
             no menses for 12 months without an alternative medical cause and confirmed by a
             follicle stimulating hormone (FSH) level in the post-menopausal range (&gt;= 25.8 IU/L).

          -  Age between 18 and 55 years, both inclusive.

          -  Body Mass Index (BMI) between 18.5 and 29.0 kg/m^2, both inclusive.

          -  Fasting plasma glucose concentration &lt;= 100 mg/dL.

          -  Considered generally healthy upon completion of medical history and screening safety
             assessments, as judged by the Investigator.

        Exclusion Criteria:

          -  Known or suspected hypersensitivity to Investigational Medicinal products ((IMP(s)) or
             related products.

          -  Receipt of any medicinal product in clinical development within 30 days or five times
             its half-life (whichever is longer) before randomization in this trial.

          -  Any history or presence of clinically relevant comorbidity, as judged by the
             investigator.

          -  Systolic blood pressure &lt; 95 mmHg or &gt;140 mmHg and/or diastolic blood pressure &lt; 50 mm
             Hg or &gt; 90 mmHg after resting for at least 5 minutes in supine position (excluding
             white-coat hypertension; therefore, a repeat test showing results within range will be
             acceptable).

          -  Pulse rate at rest outside the range of 50-90 beats per minute.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Oliver Klein, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Profil Institut für Stoffwechselforschung GmbH Hellersbergstr. 9 D-41460 Neuss</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Profil Mainz GmbH &amp; Co. KG Malakoff-Passage,Rheinstraße 4C D-55116</name>
      <address>
        <city>Mainz</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Profil Institut für Stoffwechselforschung GmbH Hellersbergstr. 9 D-41460 Neuss</name>
      <address>
        <city>Neuss</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>July 4, 2019</study_first_submitted>
  <study_first_submitted_qc>July 13, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 17, 2019</study_first_posted>
  <last_update_submitted>January 29, 2020</last_update_submitted>
  <last_update_submitted_qc>January 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin, Globin Zinc</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

